** Amgen Inc AMGN.O down 2.6% to $283.41 ahead of Q1 results due after the closing bell
** The biotech company is expected to post adj EPS of $4.30 on revenue of $8.06 bln, per LSEG data, vs yr-ago results of $3.96 per share in earnings and $7.45 bln in revenue
** AMGN has met or beat EPS estimate in seven of past eight qtrs, with most recent miss in Q2 2024
** Investors will look for any comments related to the potential effect of the Trump administration's tariffs on pharmaceuticals
** Of the 33 analysts that cover AMGN, the breakdown of recommendations is 16 "strong buy" or "buy," 14 "hold" and 3 "sell" or "strong sell" ratings
** Median price target of $329 is up from $316 on Feb 1
** With moves on Thurs, AMGN shares up ~9% YTD vs ~4% drop in the Dow Industrials .DJI
** AMGN options imply a 4.5% swing for the shares, in either direction, by Fri; that is just below the 5% move the stock has logged on the day after results over the last 8-qtrs, according to Trade Alert
(Reporting by Chuck Mikolajczak, additional reporting by Saqib Ahmed)
((charles.mikolajczak@tr.com; @chuckmik.bsky.social))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.